In July 2015, Dr. Temple joined the Tau Consortium, a highly collaborative, international group of investigators studying Tauopathies, which are neurodegenerative diseases like Alzheimer’s Disease, in which a protein called Tau misfolds and accumulates in the brain.  The Tau Consortium is funded by the Rainwater Charitable Foundation and is made up of scientists and clinicians working to understand what leads to tauopathies and to develop treatments and ultimately cure these disorders.  As part of the consortium, Dr. Temple helps lead a group of stem cell investigators from the University of California, Harvard, Washington University and Mount Sinai, New York, who are focused on developing  “disease in a dish” models to answer questions related to disease mechanism.  One key resource from this work is a world-class collection of induced pluripotent stem cells (iPSCs) generated from blood samples or small skin biopsies donated by patients carrying mutations linked to tauopathies or by healthy individuals. Currently, the iPSC collection includes seven different MAPT mutations and lines from several donors with progressive supranuclear palsy (PSP). Our goal is to continue to expand the collection each year with new and interesting mutations that will add to the research enterprise. Work is underway to create corrected isogenic controls for several of these lines. In addition, we plan to include de novo MAPT mutations introduced into normal, healthy control lines.

     The MAPT iPSC collection is now available to investigators in both for-profit and non-profit organizations. Please use the links below for more information about the collection, and the documentation process required to obtain these lines.

For more information please contact Khadijah Onanuga Ph.D., PMP [ ]